Xenna Corporation – Trademark Portfolio
Entity Type: 03
Xenna Corporation holds 17 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 3 (Cosmetics & Cleaning) — 15 filings in this category. The portfolio also extends into Class 5 (Pharmaceuticals) across 3 Nice Classification classes. Currently, 4 trademarks are registered. Notable registered marks include NONYX, XENNA, CALMSCALP, and CALMSKIN COMPLETE. The owner is based in Princeton, NJ.
130 Nassau Street Suite 250
Princeton, NJ 08542
Showing of trademarks Trademarks
Trademark Classifications
Xenna Corporation's trademark portfolio spans 3 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Bleaching preparations and other substances for laundry use; cleaning, polishing, scouring
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Advertising; business management; business administration; office functions
Frequently Asked Questions
How many trademarks does Xenna Corporation have?
Xenna Corporation has 17 U.S. trademarks filed with the USPTO. Of these, 4 registered, 5 abandoned, 8 cancelled.
What trademark classes does Xenna Corporation file in?
Xenna Corporation files trademarks across 3 Nice Classification classes. The most active classes are Class 3 (Cosmetics & Cleaning), Class 5 (Pharmaceuticals), Class 35 (Advertising & Business). Class 3 covers bleaching preparations and other substances for laundry use; cleaning, polishing, scouring.
What are Xenna Corporation's most well-known trademarks?
Xenna Corporation's registered trademark portfolio includes well-known marks such as NONYX, XENNA, CALMSCALP, and CALMSKIN COMPLETE. These are among 4 currently registered trademarks in the portfolio.
What is Xenna Corporation's trademark registration success rate?
Xenna Corporation has a 24% trademark registration rate, with 4 out of 17 resolved applications resulting in successful registration. Currently, 0 applications are pending review.